Villarreal-Ramos B, Manser J, Collins R A, Dougan G, Chatfield S N, Howard C J
Institute for Animal Health, Newbury, Berkshire, UK.
Vaccine. 1998 Jan;16(1):45-54. doi: 10.1016/s0264-410x(97)00156-4.
Salmonella aro vaccines are able to confer solid protection against homologous virulent challenge in several animal species. Calves were protected against virulent S. typhimurium challenge following administration of a single oral dose of live BRD562 vaccine. Immune responses elicited by the S. typhimurium aro vaccine strain BRD562 were studied following administration to calves by either the oral or subcutaneous route. Serum antibodies to Salmonella polypeptides, following oral or subcutaneous vaccination, were detected by immunoblotting and the route of inoculation found to affect both the antibody isotype and the antigens detected. Oral, but not subcutaneous, immunisation induced bovine serum IgA antibodies against Salmonella antigens of 30 kDa and 65 kDa and bovine IgG2 antibodies against a 35 kDa antigen. Subcutaneous vaccination triggered responses against antigens of 52 kDa, 54 kDa and 57 kDa which were not detected by immune plasma of animals immunised orally. Antibody responses to LPS were poor in animals inoculated by either route. Subcutaneous vaccination elicited T-cell responses against Salmonella antigens as measured by in vitro peripheral blood cell thymidine incorporation. These studies show that the S. typhimurium vaccine strain BRD562 is capable of inducing both humoral and cellular immune responses. Further studies are necessary to identify the nature of the antigens responsible for protection. Oral or subcutaneous inoculation of BRD562(pTETnir15) failed to induce serum antibodies against the fragment C of tetanus toxin (TetC) but was effective in mice. Oral vaccination with this recombinant vaccine induced mucosal IgA against TetC. This is the first time that Salmonella recombinant vaccines have been shown to successfully elicit antibodies against a guest antigen in cattle after one single oral inoculation.
沙门氏菌aro疫苗能够在多种动物物种中对同源强毒攻击提供可靠的保护。给犊牛口服单剂量活BRD562疫苗后，可保护其免受强毒鼠伤寒沙门氏菌的攻击。通过口服或皮下途径给犊牛接种鼠伤寒沙门氏菌aro疫苗株BRD562后，研究了其引发的免疫反应。通过免疫印迹法检测口服或皮下接种疫苗后血清中针对沙门氏菌多肽的抗体，发现接种途径会影响抗体亚型和所检测到的抗原。口服免疫（而非皮下免疫）诱导产生了针对30 kDa和65 kDa沙门氏菌抗原的牛血清IgA抗体以及针对35 kDa抗原的牛IgG2抗体。皮下接种引发了针对52 kDa、54 kDa和57 kDa抗原的反应，而口服免疫动物的免疫血浆未检测到这些反应。两种接种途径的动物对LPS的抗体反应均较弱。皮下接种通过体外外周血细胞胸苷掺入法检测到针对沙门氏菌抗原的T细胞反应。这些研究表明，鼠伤寒沙门氏菌疫苗株BRD562能够诱导体液免疫和细胞免疫反应。有必要进一步研究以确定负责保护作用的抗原的性质。口服或皮下接种BRD562(pTETnir15)未能诱导产生针对破伤风毒素片段C（TetC）的血清抗体，但对小鼠有效。用这种重组疫苗进行口服接种可诱导产生针对TetC的黏膜IgA。这是首次证明沙门氏菌重组疫苗在单次口服接种后能成功在牛体内引发针对外来抗原的抗体。
